August 2021 - Page 2 of 4 - PsychedelicNewsWire (PNW)

FridayAug 20, 2021 2:00 pm

Salvia Divinorum: The Less-Known Psychedelic and Its Properties

The popularity of psychedelics has been growing as the research conducted on these substances for their therapeutic benefits increases. Substances such as DMT, LSD, MDMA and psilocybin are the most studied as well as the most common psychedelics while others, including salvia divinorum, aren’t popularly known. Salvia divinorum is a psychoactive plant used in rituals in Mazatec shamanic ceremonies. The plant species is found in the mountainous Sierra Mazateca area near Mexico’s Oaxaca City. Its leaves contain a compound known as salvinorin A, which induces the plant’s psychoactive effects when the leaves are smoked or chewed. This compound’s presence hinders…

ThursdayAug 19, 2021 2:30 pm

Florida Researchers Seek Answers on Ability of Psychedelics to Treat Psychological Conditions

Research on psychedelic substances and the therapeutic properties they possess that can be used to treat various mental health conditions has been increasing. For example, researchers in Florida are focused on studying psilocybin, which is the active compound found in magic mushrooms. Earlier in 2019, the FDA granted breakthrough therapy status to psilocybin treatments under development, which made it easier for the Usona Institute, a nonprofit organization, to conduct studies on the psychedelic. Dr. Charles Raison, the institute’s director of clinical and translational research, stated that the organization had sites in seven states and was planning to establish a duo…

ThursdayAug 19, 2021 11:56 am

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’

Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research The Vancouver-based company was formed in 2019 as the ‎first psychedelic umbrella platform The Delic self-sustaining Ecosystem covers three main areas: media, health, and science On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company, a legacy counterculture distributor of psychedelic media An estimated $238 billion is spent annually in the U.S. on mental health treatments and ancillary services University-led and FDA-approved studies are positioning North America as a leading region in the advancement…

ThursdayAug 19, 2021 11:23 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Cybin subsidiary achieved certain milestones as outlined in acquisition agreement Adelia brought numerous advantages to company Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin's (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain milestones for the year as outlined in the acquisition agreement, resulting in Adelia shareholders receiving common shares in Cybin. Cybin closed on the acquisition of Adelia late last year, with the company noting…

ThursdayAug 19, 2021 10:59 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials

Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies Calvert Labs shall perform TRP-8803 and TRP-8802 are psilocybin-based products being evaluated under Tryp’s PFN program Tryp intends to use TRP-8802 in the Phase 2a clinical trials, while TRP-8803 will be used in Phase 2b clinical trials and beyond The San Diego-based pharmaceutical company, Tryp…

WednesdayAug 18, 2021 1:45 pm

Praying, Using Psychedelic Substances May Activate Similar Regions in Brain

Prayer and psychedelic substances have both demonstrated that they have antidepressant, analgesic and anxiolytic properties. This is in addition to showing that they can both induce alterations of mood and perception. Various studies using functional magnetic resonance imaging have identified cortical regions and brain structures that become active when individuals undergo intense spiritual experiences or are exposed to various psychedelic substances. Spiritual retreat participants usually report enhanced spiritual well-being or improved sense of spirituality, which researchers think may be linked to changes in functional connectivity between regions in the brain that were actively involved in the production of those feelings.…

TuesdayAug 17, 2021 1:20 pm

New Poll Suggests 80% of Canadians Support Legalization of Psilocybin for Medical Use

A recent survey reported that four out of every five Canadians are in favor of the therapeutic use of psilocybin for individuals who suffer from a terminal condition; those respondents urge the government to establish a regulatory framework to allow its use in these circumstances. The poll was carried out by Nanos Research and commissioned by the Canadian Psychedelic Association (“CPA”). For the survey, more than 1,000 Canadian adults were interviewed between June 30, 2021, and July 5, 2021. More than 75% of the survey’s respondents stated that they supported the establishment of a legal regulatory model to facilitate the…

MondayAug 16, 2021 1:05 pm

Ibogaine May Combat Cravings, Withdrawal Symptoms in Addicts

While not many effective treatments for substance addiction exist, approximately 22 million people in America are on their way to recovery. Unfortunately, recovered addicts constantly stare the risk of relapse in the face, and a number of medications to curb withdrawal symptoms and cravings are being considered. Ibogaine, a psychedelic substance found in the iboga plant, has grown in popularity due to its ability to help combat addiction. Ibogaine has its roots in West Africa, where it is harvested from a shrub called Tabernanthe iboga. The indigenous people have used it in small doses for millennia to combat thirst, hunger…

FridayAug 13, 2021 10:45 am

What We Should Know About Psychedelic-Assisted Therapy

Research on psychedelic-assisted therapy has demonstrated the many benefits the treatment approach has. With more investors becoming receptive to the use of this approach as an alternative treatment in the future, some biopharmaceutical companies that aim to make psychedelic drugs to treat various mental health conditions have launched their IPOs. The companies in question include Compass Pathways, MindMed and Atai Life Sciences; the companies went public in November 2020, April 2021 and June 2021 respectively. Together, these firms have more than nine psychedelic therapy medications in their product pipelines. So how do psychedelic drugs work for therapy? Psychedelics are known…

FridayAug 13, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast

Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industry During the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disorders Greg also shared the challenges that the industry is facing currently, mostly to do with legislation McKee also shared how people can help the company and the industry by pushing for the decriminalization of psychedelics and taking part in clinical trials On August 2, 2021, the Dealmaker Podcast posted an interview with Greg McKee, the Chief Executive Officer (“CEO”) of…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: August 2021